---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-003854"
form_type: "8-K"
ticker: "ALNY"
cik: "0001178670"
company_name: "ALNYLAM PHARMACEUTICALS, INC."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:00:59.912537+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Alnylam prelim 2023 product rev $1.24B (+39% YoY); Q4 growth across all drugs

## Summary
- Full-year 2023 global net product revenues $1,241M, up 39% YoY (39% constant currency).
- Q4 2023 revenues: ONPATTRO $79M, AMVUTTRA $175M, GIVLAARI $59M, OXLUMO $33M.
- Year-end cash & investments ~$2.4B, up from $2.2B at end of 2022.
- Over 4,060 patients on ONPATTRO/AMVUTTRA; over 650 on GIVLAARI, over 430 on OXLUMO at year-end 2023.
- Management cites strong patient demand and commercial execution; HELIOS-B readout expected early 2024.

## SEC filing metadata
- accession: 0001193125-24-003854
- form_type: 8-K
- ticker: ALNY
- cik: 0001178670
- company_name: ALNYLAM PHARMACEUTICALS, INC.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/0001193125-24-003854-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-003854
- JSON: https://secwatch.observer/filing/0001193125-24-003854.json
- Plain text: https://secwatch.observer/filing/0001193125-24-003854.txt

## Key facts
- Earnings Releases
  ALNYLAM PHARMACEUTICALS, INC. reported fourth quarter 2023 results: revenue $346 million.
  - Period: fourth quarter 2023
  - Revenue: $346 million
  - Result: preliminary results
  source text: On January 7, 2024, Alnylam Pharmaceuticals, Inc. (the “Company”) announced its preliminary fourth quarter and full year 2023 global net product revenues of approximately $346 million and $1,241 million, respectively, for ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran) and OXLUMO® (lumasiran).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/0001193125-24-003854-index.htm
- Earnings Releases
  ALNYLAM PHARMACEUTICALS, INC. reported full year 2023 results: revenue $1,241 million.
  - Period: full year 2023
  - Revenue: $1,241 million
  - Result: preliminary results
  source text: On January 7, 2024, Alnylam Pharmaceuticals, Inc. (the “Company”) announced its preliminary fourth quarter and full year 2023 global net product revenues of approximately $346 million and $1,241 million, respectively, for ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran) and OXLUMO® (lumasiran).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/0001193125-24-003854-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.